Increasing Low End of Guidance: $1,025 Million – $1,030 Million, up 21% – 22%
DANVERS, Mass.–(BUSINESS WIRE)–ABIOMED, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended December 31, 2021.
Q3 financial summary and operational highlights:
- Revenue for the quarter totaled $261 million, an increase of 13% compared to $232 million during the same period of the prior fiscal year. In constant currency,* revenue increased 14% compared to the same period of the prior fiscal year.
- Worldwide Impella® heart pump product revenue for the quarter totaled $249 million, an increase of 13% compared to $221 million during the same period of the prior fiscal year. In constant currency,* revenue increased 14% compared to the same period of the prior fiscal year.
- U.S. Impella product revenue for the quarter totaled $201 million, an increase of 12% compared to $180 million during the same period of the prior fiscal year due to a 10% increase in patient utilization.
- Outside the U.S., Impella product revenue for the quarter totaled $48 million, an increase of 16% compared to $41 million during the same period of the prior fiscal year. In constant currency,* outside the U.S., Impella product revenue increased 22% compared to the same period of the prior fiscal year.
- Europe product revenue for the quarter totaled $31 million, an increase of 13% compared to $28 million during the same period of the prior fiscal year. In constant currency,* Europe product revenue increased 18% compared to the same period of the prior fiscal year due to a 13% increase in patient utilization.
- Japan product revenue for the quarter totaled $14 million, an increase of 16% compared to $12 million during the same period of the prior fiscal year. In constant currency,* Japan product revenue increased 27% compared to the same period of the prior fiscal year due to a 35% increase in patient utilization.
- Gross margin for the quarter was 81.8% compared to 82.3% during the same period of the prior fiscal year.
- Non-GAAP income from operations* was $65 million or 24.9% non-GAAP operating margin* for the quarter, compared to $71 million non-GAAP income from operations* or 30.8% non-GAAP operating margin* during the same period of the prior fiscal year, primarily due to increased investment in innovation, clinical evidence and building a premier distribution team. GAAP income from operations was $65 million or 24.7% GAAP operating margin for the quarter, compared to $71 million GAAP income from operations or 30.8% GAAP operating margin during the same period of the prior fiscal year.
- Non-GAAP net income* was $52 million, or $1.13 per diluted share, compared to non-GAAP net income* of $54 million, or $1.17 per diluted share during the same period of the prior fiscal year. GAAP net income was $46 million, or $1.00 per diluted share compared to $62 million GAAP net income or $1.35 per diluted share during the same period of the prior fiscal year.
- The company generated operating cash flows of $90 million during the quarter. As of December 31, 2021, the company had $932 million of cash and cash equivalents and marketable securities and no debt.
- On November 3, the company announced the 2021 guidelines of the European Society of Cardiology (ESC) for treatment of acute heart failure patients, including patients in cardiogenic shock, raised the recommendation level for short-term mechanical circulatory support systems, such as Impella heart pumps, from Class IIb (“may be considered”) to Class IIa (“should be considered”). This is the first update of the ESC guidelines in five years and reflects the growing body of robust clinical evidence supporting the use of Impella for cardiogenic shock patients.
- On November 4, physician experts and principal investigators of the PROTECT IV RCT, the RECOVER IV RCT and the STEMI Door-to-Unloading RCT presented robust, high-quality data and clinical studies of Impella heart pumps at Transcatheter Cardiovascular Therapeutics (TCT) 2021, the annual scientific symposium of the Cardiovascular Research Foundation. Presentations included the final results of the PROTECT III and Restore EF prospective studies, an update on the on-going RCTs and a review of the clinical experience with the new 9 French Impella ECP heart pump. The presentations are available for on-demand viewing at this link.
- On January 10, the company announced that regulators in three countries granted approvals to Impella surgical products. In Japan, Impella 5.5 with SmartAssist has received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). In the United States, the Food and Drug Administration (FDA) granted an Early Feasibility Study (EFS) Investigational Device Exemption (IDE) to Impella BTR (Bridge-to-Recovery). In Hong Kong, Impella 5.5 with SmartAssist has received approval from the Medical Device Division (MDD).
- On January 12, Chairman, President and Chief Executive Officer, Michael R. Minogue, presented at the 40th Annual J.P. Morgan Healthcare Conference. The presentation provides a brief overview of the company and a deep dive on Abiomed’s breakthrough innovation, robust clinical evidence, and premier clinical field team.
- On January 12, the company announced the successful results of the first-in-human EFS of the preCARDIA system. The preCARDIA system is designed to improve decongestion in acutely decompensated heart failure (ADHF) patients by intermittently occluding the superior vena cava. The study met the safety and feasibility endpoints, and the results of the study were published in the journal Circulation: Heart Failure.
“Despite a slower start in October due to the COVID resurgence and hospital labor shortages, our Abiomed 2.0 playbook allowed us to adapt and execute, grow sequentially, and support the most patients ever in a quarter. These record results would not have been possible without the dedication of our customers and employees supporting critically ill patients 24 x 7 on-site, online and in the cloud with Impella Connect,” said Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive Officer. “Our focus on extending our lead in innovation, advancing clinical evidence, and building a premier commercial team enables the pursuit of becoming the global standard of care for hemodynamic support.”
FISCAL YEAR 2022 OUTLOOK
The company is increasing the lower end of its fiscal year 2022 revenue guidance to a range of $1,025 million to $1,030 million with growth of 21% – 22% versus prior year. This compares to the previous quarter guidance of $1,010 million to $1,030 million, an increase of 19% – 22%. The company expects its fiscal year 2022 non-GAAP operating margin* to be in the range of 24% – 25%.
*ABOUT NON-GAAP FINANCIAL MEASURES
To supplement its condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the company uses non-GAAP financial measures as described below. The company uses these non-GAAP financial measures for financial and operational decision-making and to evaluate period-to-period comparisons. The company believes that these non-GAAP financial measures provide meaningful supplemental information regarding its performance and liquidity. The company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing its performance and when planning, forecasting, and analyzing future periods. The company believes these non-GAAP financial measures are useful to investors because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by institutional investors and the analyst community to help them analyze the performance of the company’s business.
The company uses the following non-GAAP financial measures:
Non-GAAP operating income: The company defines non-GAAP operating income as operating income, excluding charges for the acquired in-process research and development related to the preCARDIA acquisition.
Non-GAAP operating margin: The company defines non-GAAP operating margin as operating margin, excluding charges for the acquired in-process research and development related to the preCARDIA acquisition.
Non-GAAP net income and net income per diluted share: The company defines non-GAAP net income and net income per diluted share as net income and net income per diluted share, excluding charges for the acquired in-process research and development related to the preCARDIA acquisition, the gain recognized on its previously owned minority interest in preCARDIA, unrealized losses/ gains on investment in Shockwave Medical and excess tax benefits associated with stock-based compensation. The company defines non-GAAP EPS as non-GAAP net income divided by non-GAAP diluted shares, which are calculated as GAAP weighted average outstanding shares plus dilutive potential shares outstanding during the period.
Constant currency: The company defines constant currency revenue growth as the change in revenue between current and prior year periods using a constant currency, the exchange rate in effect during the applicable prior year period. The company presents constant currency revenue growth because management believes it provides meaningful information regarding the company’s revenue results on a consistent and comparable basis.
Refer to the “Reconciliation of GAAP to Non-GAAP Financial Measures” section of this press release.
The company reports non-GAAP financial measures in addition to, and not as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies. The company believes it is useful to exclude certain items because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods. The company believes that non-GAAP financial measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business.
EARNINGS CONFERENCE CALL DETAILS
The company will host a conference call to discuss the quarterly results at 8:00 a.m. ET on Thursday, February 3, 2022. The conference call will be hosted by Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Vice President and Chief Financial Officer.
To listen to the call live, please tune into the webcast via https://investors.abiomed.com/events-presentations or dial (844) 200-6205; the international number is (929) 526-1599 access code 898485. A replay of this conference call will be available until Thursday, February 10, 2022. The replay phone number is (866) 813-9403; the international number is +44 204 525 0658. The replay access code is 017050.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com. Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, Impella 5.5, Impella Connect, and SmartAssist are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries. Impella ECP, Impella XR Sheath, Impella BTR, CVAD STUDY, STEMI DTU, Automated Impella Controller and Abiomed Breethe OXY-1 System and preCARDIA are pending trademarks of Abiomed, Inc.
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including, without limitation, statements regarding development of Abiomed’s existing and new products, the company’s progress toward commercial growth, future opportunities and expected regulatory approvals and statements in the paragraph under “Fiscal Year 2022 Outlook” section regarding certain business metrics on either or both a GAAP or non-GAAP basis. All statements, other than statements of historical facts, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. The company’s actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including, without limitation: the scope, scale and duration of the impact of the COVID-19 pandemic, the company’s dependence on Impella® products for all of its revenues; the company’s ability to successfully compete against its existing or potential competitors; the acceptance of the company’s products by cardiac surgeons and interventional cardiologists; long sales and training cycles associated with expansion into new hospital cardiac centers; reduced market acceptance of the company’s products due to lengthy clinician training process; the company’s ability to effectively manage its growth; the company’s ability to successfully commercialize its products; the company’s ability to obtain regulatory approvals and market and sell its products in certain jurisdictions; enforcement actions and product liability suits relating to off-label uses of the company’s products; unsuccessful clinical trials or procedures relating to products under development; the company’s ability to maintain compliance with regulatory requirements; the failure of third-party payers to provide reimbursement of the company’s products; the company’s ability to increase manufacturing capacity to support continued demand for its products; the company or its vendors’ failure to achieve and maintain high manufacturing standards; the failure of the company’s suppliers to provide the components the company requires; the company’s ability to expand its direct sales activities into international markets; the outcome of ongoing securities class action litigation relating to our public disclosures, the company’s ability to integrate acquired companies into its operations and other risks and challenges detailed in the company’s filings with the Securities and Exchange Commission (the “SEC”), including the most recently filed Annual Report on Form 10-K and the filings subsequently filed with or furnished to the SEC. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. Unless otherwise required by law, the company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
| Abiomed, Inc. and Subsidiaries | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (Unaudited) | ||||||||
| (in thousands) | ||||||||
| December 31, 2021 | March 31, 2021 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents |
$ |
144,255 |
|
$ |
232,710 |
|
||
| Short-term marketable securities |
|
524,966 |
|
|
350,985 |
|
||
| Accounts receivable, net |
|
88,952 |
|
|
97,179 |
|
||
| Inventories, net |
|
90,199 |
|
|
81,059 |
|
||
| Prepaid expenses and other current assets |
|
36,634 |
|
|
26,032 |
|
||
| Total current assets |
|
885,006 |
|
|
787,965 |
|
||
| Long-term marketable securities |
|
262,635 |
|
|
264,085 |
|
||
| Property and equipment, net |
|
196,880 |
|
|
197,129 |
|
||
| Goodwill |
|
77,449 |
|
|
78,568 |
|
||
| Other intangibles, net |
|
40,278 |
|
|
42,150 |
|
||
| Deferred tax assets |
|
3,680 |
|
|
11,380 |
|
||
| Other assets |
|
126,949 |
|
|
113,082 |
|
||
| Total assets |
$ |
1,592,877 |
|
$ |
1,494,359 |
|
||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable |
$ |
32,066 |
|
$ |
34,842 |
|
||
| Accrued expenses |
|
66,668 |
|
|
66,046 |
|
||
| Deferred revenue |
|
24,867 |
|
|
24,322 |
|
||
| Other current liabilities |
|
3,195 |
|
|
3,759 |
|
||
| Total current liabilities |
|
126,796 |
|
|
128,969 |
|
||
| Other long-term liabilities |
|
10,805 |
|
|
10,162 |
|
||
| Contingent consideration |
|
21,539 |
|
|
24,706 |
|
||
| Deferred tax liabilities |
|
799 |
|
|
847 |
|
||
| Total liabilities |
|
159,939 |
|
|
164,684 |
|
||
| Stockholders’ equity: | ||||||||
| Class B Preferred Stock, $.01 par value |
|
— |
|
|
— |
|
||
| 1,000 shares authorized; issued and outstanding – none | ||||||||
| Common stock, $.01 par value |
|
455 |
|
|
453 |
|
||
| 100,000 shares authorized; 48,229 and 47,929 shares issued as of December 31, 2021 and March 31, 2021, respectively | ||||||||
| 45,516 and 45,271 shares outstanding as of December 31, 2021 and March 31, 2021, respectively | ||||||||
| Additional paid in capital |
|
853,210 |
|
|
800,690 |
|
||
| Retained earnings |
|
904,187 |
|
|
828,007 |
|
||
| Treasury stock at cost – 2,713 and 2,658 shares as of December 31, 2021 and March 31, 2021, respectively |
|
(304,425 |
) |
|
(288,030 |
) |
||
| Accumulated other comprehensive loss |
|
(20,489 |
) |
|
(11,445 |
) |
||
| Total stockholders’ equity |
|
1,432,938 |
|
|
1,329,675 |
|
||
| Total liabilities and stockholders’ equity |
$ |
1,592,877 |
|
$ |
1,494,359 |
|
||
| Abiomed, Inc. and Subsidiaries | |||||||||||||
| Condensed Consolidated Statements of Operations | |||||||||||||
| (Unaudited) | |||||||||||||
| (in thousands, except per share data) | |||||||||||||
|
For the Three Months Ended December 31, |
|
For the Nine Months Ended December 31, |
|||||||||||
|
|
2021 |
|
|
|
2020 |
|
|
2021 |
|
|
2020 |
||
| Revenue |
$ |
261,176 |
|
$ |
231,663 |
$ |
761,903 |
$ |
606,277 |
||||
| Costs and expenses: | |||||||||||||
| Cost of revenue |
|
47,627 |
|
|
41,110 |
|
136,701 |
|
115,829 |
||||
| Research and development |
|
40,869 |
|
|
33,004 |
|
119,618 |
|
89,886 |
||||
| Selling, general and administrative |
|
107,618 |
|
|
86,198 |
|
313,881 |
|
233,809 |
||||
| Acquired in-process research and development |
|
496 |
|
|
— |
|
115,986 |
|
— |
||||
|
|
196,610 |
|
|
160,312 |
|
686,186 |
|
439,524 |
|||||
| Operating income |
|
64,566 |
|
|
71,351 |
|
75,717 |
|
166,753 |
||||
| Other (loss) income: | |||||||||||||
| Investment income, net |
|
891 |
|
|
1,449 |
|
2,918 |
|
5,668 |
||||
| Other (loss) income, net |
|
(7,580 |
) |
|
7,935 |
|
37,163 |
|
42,305 |
||||
|
|
(6,689 |
) |
|
9,384 |
|
40,081 |
|
47,973 |
|||||
| Income before income taxes |
|
57,877 |
|
|
80,735 |
|
115,798 |
|
214,726 |
||||
| Income tax provision |
|
12,125 |
|
|
18,867 |
|
39,618 |
|
46,057 |
||||
| Net income |
$ |
45,752 |
|
$ |
61,868 |
$ |
76,180 |
$ |
168,669 |
||||
| Net income per share – basic |
$ |
1.01 |
|
$ |
1.37 |
$ |
1.68 |
$ |
3.74 |
||||
| Weighted average shares outstanding – basic |
|
45,508 |
|
|
45,201 |
|
45,419 |
|
45,105 |
||||
| Net income per share – diluted |
$ |
1.00 |
|
$ |
1.35 |
$ |
1.66 |
$ |
3.69 |
||||
| Weighted average shares outstanding – diluted |
|
45,921 |
|
|
45,706 |
|
45,851 |
|
45,653 |
||||
| Abiomed, Inc. and Subsidiaries | |||||||||||||||
| Reconciliation of GAAP to Non-GAAP Financial Measures | |||||||||||||||
| (Unaudited) | |||||||||||||||
| (in thousands, except per share data) | |||||||||||||||
| For the Three Months Ended December 31, | For the Nine Months Ended December 31, | ||||||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||
| GAAP operating income |
$ |
64,566 |
|
$ |
71,351 |
|
$ |
75,717 |
|
$ |
166,753 |
|
|||
| Acquired in-process research and development (1) |
|
496 |
|
|
— |
|
|
115,986 |
|
|
— |
|
|||
| Non-GAAP operating income |
$ |
65,062 |
|
$ |
71,351 |
|
$ |
191,703 |
|
$ |
166,753 |
|
|||
| GAAP operating margin |
|
24.7 |
% |
|
30.8 |
% |
|
9.9 |
% |
|
27.5 |
% |
|||
| Non-GAAP operating margin |
|
24.9 |
% |
|
30.8 |
% |
|
25.2 |
% |
|
27.5 |
% |
|||
| GAAP net income |
|
45,752 |
|
$ |
61,868 |
|
$ |
76,180 |
|
$ |
168,669 |
|
|||
| Acquired in-process research and development (1) |
|
496 |
|
|
— |
|
|
115,986 |
|
|
— |
|
|||
| Gain on previously held interest in preCARDIA (2) |
|
— |
|
|
— |
|
|
(20,980 |
) |
|
— |
|
|||
| Loss (gain) on investment in Shockwave Medical (3) |
|
6,164 |
|
|
(6,237 |
) |
|
(10,748 |
) |
|
(32,338 |
) |
|||
| Excess tax benefits on stock-based compensation (4) |
|
(338 |
) |
|
(1,909 |
) |
|
(10,139 |
) |
|
(10,363 |
) |
|||
| Non-GAAP net income |
$ |
52,074 |
|
$ |
53,722 |
|
$ |
150,299 |
|
$ |
125,968 |
|
|||
| GAAP diluted net income per share |
$ |
1.00 |
|
$ |
1.35 |
|
$ |
1.66 |
|
$ |
3.69 |
|
|||
| Acquired in-process research and development (1) |
|
0.01 |
|
|
— |
|
|
2.53 |
|
|
— |
|
|||
| Gain on previously held interest in preCARDIA (2) |
|
— |
|
|
— |
|
|
(0.46 |
) |
|
— |
|
|||
| Loss (gain) on investment in Shockwave Medical (3) |
|
0.13 |
|
|
(0.14 |
) |
|
(0.23 |
) |
|
(0.71 |
) |
|||
| Excess tax benefits on stock-based compensation (4) |
|
(0.01 |
) |
|
(0.04 |
) |
|
(0.22 |
) |
|
(0.23 |
) |
|||
| Non-GAAP diluted net income per share |
$ |
1.13 |
|
$ |
1.17 |
|
$ |
3.28 |
|
$ |
2.75 |
|
|||
| GAAP diluted weighted-average shares outstanding |
|
45,921 |
|
|
45,706 |
|
|
45,851 |
|
|
45,653 |
|
|||
| Non-GAAP diluted weighted-average shares outstanding |
|
45,921 |
|
|
45,706 |
|
|
45,851 |
|
|
45,653 |
|
|||
| Notes: | |||||||
| (1) In May 2021, the company acquired the remaining interest in preCARDIA for $82.8 million. The company determined that substantially all of the fair value of the acquisition related to the acquired in-process research and development asset, which resulted in accounting for the transaction as an asset acquisition. The fair value of the acquired in-process research and development asset of $115.5 million is primarily comprised of the net consideration paid for the acquired remaining interest of $82.8 million and our previously owned minority interest in preCARDIA of $32.4 million. During the three months ended December 31, 2021, the Company made a holdback payment of $0.5 million to former shareholders of preCARDIA. Since the acquired technology platform is pre-commercial and has not reached technical feasibility as defined by the accounting rules, the cost of the in-process research and development asset was expensed, resulting in a charge of $116 million for the nine months ended December 31, 2021. | |||||||
| (2) The company recognized a gain of $21 million related to its previously owned minority interest in preCARDIA as described in note (1) above, within the condensed consolidated statement of operations for the nine months ended December 31, 2021. | |||||||
| (3) Amount represents the unrealized loss (gain) on investment in Shockwave Medical in each respective period presented. The company recognized an unrealized loss on investment in Shockwave Medical of $8.2 million ($6.2 million, net of tax benefit) and an unrealized gain of $8.3 million ($6.2 million, net of tax benefit) within other (loss) income, net for the three months ended December 31, 2021 and 2020, respectively. The company recognized an unrealized gain on investment in Shockwave Medical of $14.3 million ($10.7 million, net of tax benefit) and $43 million ($32.3 million, net of tax benefit) within other (loss) income, net for the nine months ended December 31, 2021 and 2020, respectively. | |||||||
| (4) Amount represents the impact of excess tax benefits associated with stock-based compensation in each respective period presented. The company recognized excess tax benefits associated with stock-based compensation of $0.3 million and $1.9 million as an income tax benefit for the three months ended December 31, 2021 and 2020, respectively. The company recognized excess tax benefits associated with stock-based compensation of $10.1 million and $10.4 million as an income tax benefit for the nine months ended December 31, 2021 and 2020, respectively. |
| Abiomed, Inc. and Subsidiaries | ||||||||||||||||
| Reconciliation of GAAP to Non-GAAP Constant Currency | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| (in thousands) | ||||||||||||||||
| Total revenue by region: | ||||||||||||||||
| For the Three Months Ended December 31, | ||||||||||||||||
|
|
2021 |
|
2020 |
% Change | Currency Impact | Constant Currency* | ||||||||||
| United States |
$ |
211,957 |
$ |
189,116 |
12 |
% |
— |
|
% |
12 |
% |
|||||
| Europe |
|
32,379 |
|
28,630 |
13 |
% |
5 |
|
% |
18 |
% |
|||||
| Japan |
|
14,021 |
|
12,012 |
17 |
% |
10 |
|
% |
27 |
% |
|||||
| Rest of world |
|
2,819 |
|
1,905 |
48 |
% |
— |
|
% |
48 |
% |
|||||
| Outside the U.S. |
|
49,219 |
|
42,547 |
16 |
% |
6 |
|
% |
22 |
% |
|||||
| Total revenue |
$ |
261,176 |
$ |
231,663 |
13 |
% |
1 |
|
% |
14 |
% |
|||||
| For the Nine Months Ended December 31, | ||||||||||||||||
|
|
2021 |
|
2020 |
% Change | Currency Impact | Constant Currency* | ||||||||||
| United States |
$ |
619,585 |
$ |
495,988 |
25 |
% |
— |
|
% |
25 |
% |
|||||
| Europe |
|
97,143 |
|
73,638 |
32 |
% |
(2 |
) |
% |
30 |
% |
|||||
| Japan |
|
37,572 |
|
31,308 |
20 |
% |
6 |
|
% |
26 |
% |
|||||
| Rest of world |
|
7,603 |
|
5,343 |
42 |
% |
— |
|
% |
42 |
% |
|||||
| Outside the U.S. |
|
142,318 |
|
110,289 |
29 |
% |
1 |
|
% |
30 |
% |
|||||
| Total revenue |
$ |
761,903 |
$ |
606,277 |
26 |
% |
— |
|
% |
26 |
% |
|||||
| Product revenue by region: | ||||||||||||||||
| For the Three Months Ended December 31, | ||||||||||||||||
|
|
2021 |
|
2020 |
% Change | Currency Impact | Constant Currency* | ||||||||||
| United States |
$ |
201,404 |
$ |
179,612 |
12 |
% |
— |
|
% |
12 |
% |
|||||
| Europe |
|
31,266 |
|
27,666 |
13 |
% |
5 |
|
% |
18 |
% |
|||||
| Japan |
|
13,575 |
|
11,663 |
16 |
% |
11 |
|
% |
27 |
% |
|||||
| Rest of world |
|
2,820 |
|
1,906 |
48 |
% |
— |
|
% |
48 |
% |
|||||
| Outside the U.S. |
|
47,661 |
|
41,235 |
16 |
% |
6 |
|
% |
22 |
% |
|||||
| Total product revenue |
$ |
249,065 |
$ |
220,847 |
13 |
% |
1 |
|
% |
14 |
% |
|||||
| For the Three Months Ended December 31, | ||||||||||||||||
|
|
2021 |
|
2020 |
% Change | Currency Impact | Constant Currency* | ||||||||||
| United States |
$ |
588,624 |
$ |
469,038 |
25 |
% |
— |
|
% |
25 |
% |
|||||
| Europe |
|
93,823 |
|
71,083 |
32 |
% |
(2 |
) |
% |
30 |
% |
|||||
| Japan |
|
36,273 |
|
30,477 |
19 |
% |
6 |
|
% |
25 |
% |
|||||
| Rest of world |
|
7,604 |
|
5,343 |
42 |
% |
— |
|
% |
42 |
% |
|||||
| Outside the U.S. |
|
137,700 |
|
106,902 |
29 |
% |
— |
|
% |
29 |
% |
|||||
| Total product revenue |
$ |
726,324 |
$ |
575,940 |
26 |
% |
— |
|
% |
26 |
% |
|||||
Contacts
For further information:
Todd Trapp
Vice President and Chief Financial Officer
978-646-1680
ttrapp@abiomed.com
Tom Langford
Director, Corporate Communications & PR
978-882-8408
tlangford@abiomed.com
